{"title":"传统心脏再同步化治疗无反应或面临挑战的3D定位引导左心室心内膜起搏治疗。","authors":"Yuzhe Song, Lijuan Huang, Hao Hu, Cheng Jiang, Feng Zhao, Peng Chang","doi":"10.6515/ACS.202507_41(4).20250310A","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aims to evaluate the feasibility, efficacy, procedural complications, and long-term outcomes of left ventricular (LV) endocardial pacing lead implantation at the latest activation site of the LV. This procedure is guided by three-dimensional (3D) mapping and performed via transseptal puncture, and targets heart failure (HF) patients who either do not respond to conventional cardiac resynchronization therapy (CRT) or face challenges in lead implantation.</p><p><strong>Methods and results: </strong>A retrospective analysis of clinical data was performed on 11 patients with dilated cardiomyopathy who were treated with LV endocardial pacing. Compared to conventional CRT, this procedure required longer operation and fluoroscopy times and higher radiation dose. Clinical improvements, as evidenced by at least one New York Heart Association class improvement, were achieved in 63.6% of the patients, with an average decrease in Minnesota Living with Heart Failure Questionnaire score of 33.8 ± 2.2 points (p < 0.05). However, complications and adverse events were noted in 3 patients (27.3%) one month postoperatively, including pocket hematomas in 3 patients (27.3%), a pocket infection in 1 patient (9.1%), and a thromboembolic event in 1 patient (9.1%). In addition, 3 patients (27.3%) had worsening HF after implantation. The estimated mortality rates at 1, 3, and 5 years post-implantation were 9.1%, 18.2%, and 27.3%, respectively.</p><p><strong>Conclusions: </strong>Implanting the LV endocardial pacing lead at the latest activation site under 3D mapping guidance via transseptal puncture offers a viable alternative for patients eligible for CRT who face challenges with LV epicardial lead implantation due to anatomical issues or CRT non-response. However, this procedure is associated with a relatively high incidence of complications, requires careful patient selection, and may necessitate lifelong anticoagulation after implantation.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"41 4","pages":"557-564"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305828/pdf/","citationCount":"0","resultStr":"{\"title\":\"Left Ventricular Endocardial Pacing Therapy Guided by 3D Mapping for Conventional Cardiac Resynchronization Therapy Non-Response or Face Challenges.\",\"authors\":\"Yuzhe Song, Lijuan Huang, Hao Hu, Cheng Jiang, Feng Zhao, Peng Chang\",\"doi\":\"10.6515/ACS.202507_41(4).20250310A\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>This study aims to evaluate the feasibility, efficacy, procedural complications, and long-term outcomes of left ventricular (LV) endocardial pacing lead implantation at the latest activation site of the LV. This procedure is guided by three-dimensional (3D) mapping and performed via transseptal puncture, and targets heart failure (HF) patients who either do not respond to conventional cardiac resynchronization therapy (CRT) or face challenges in lead implantation.</p><p><strong>Methods and results: </strong>A retrospective analysis of clinical data was performed on 11 patients with dilated cardiomyopathy who were treated with LV endocardial pacing. Compared to conventional CRT, this procedure required longer operation and fluoroscopy times and higher radiation dose. Clinical improvements, as evidenced by at least one New York Heart Association class improvement, were achieved in 63.6% of the patients, with an average decrease in Minnesota Living with Heart Failure Questionnaire score of 33.8 ± 2.2 points (p < 0.05). However, complications and adverse events were noted in 3 patients (27.3%) one month postoperatively, including pocket hematomas in 3 patients (27.3%), a pocket infection in 1 patient (9.1%), and a thromboembolic event in 1 patient (9.1%). In addition, 3 patients (27.3%) had worsening HF after implantation. The estimated mortality rates at 1, 3, and 5 years post-implantation were 9.1%, 18.2%, and 27.3%, respectively.</p><p><strong>Conclusions: </strong>Implanting the LV endocardial pacing lead at the latest activation site under 3D mapping guidance via transseptal puncture offers a viable alternative for patients eligible for CRT who face challenges with LV epicardial lead implantation due to anatomical issues or CRT non-response. However, this procedure is associated with a relatively high incidence of complications, requires careful patient selection, and may necessitate lifelong anticoagulation after implantation.</p>\",\"PeriodicalId\":6957,\"journal\":{\"name\":\"Acta Cardiologica Sinica\",\"volume\":\"41 4\",\"pages\":\"557-564\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305828/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Cardiologica Sinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6515/ACS.202507_41(4).20250310A\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cardiologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6515/ACS.202507_41(4).20250310A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Left Ventricular Endocardial Pacing Therapy Guided by 3D Mapping for Conventional Cardiac Resynchronization Therapy Non-Response or Face Challenges.
Aims: This study aims to evaluate the feasibility, efficacy, procedural complications, and long-term outcomes of left ventricular (LV) endocardial pacing lead implantation at the latest activation site of the LV. This procedure is guided by three-dimensional (3D) mapping and performed via transseptal puncture, and targets heart failure (HF) patients who either do not respond to conventional cardiac resynchronization therapy (CRT) or face challenges in lead implantation.
Methods and results: A retrospective analysis of clinical data was performed on 11 patients with dilated cardiomyopathy who were treated with LV endocardial pacing. Compared to conventional CRT, this procedure required longer operation and fluoroscopy times and higher radiation dose. Clinical improvements, as evidenced by at least one New York Heart Association class improvement, were achieved in 63.6% of the patients, with an average decrease in Minnesota Living with Heart Failure Questionnaire score of 33.8 ± 2.2 points (p < 0.05). However, complications and adverse events were noted in 3 patients (27.3%) one month postoperatively, including pocket hematomas in 3 patients (27.3%), a pocket infection in 1 patient (9.1%), and a thromboembolic event in 1 patient (9.1%). In addition, 3 patients (27.3%) had worsening HF after implantation. The estimated mortality rates at 1, 3, and 5 years post-implantation were 9.1%, 18.2%, and 27.3%, respectively.
Conclusions: Implanting the LV endocardial pacing lead at the latest activation site under 3D mapping guidance via transseptal puncture offers a viable alternative for patients eligible for CRT who face challenges with LV epicardial lead implantation due to anatomical issues or CRT non-response. However, this procedure is associated with a relatively high incidence of complications, requires careful patient selection, and may necessitate lifelong anticoagulation after implantation.
期刊介绍:
Acta Cardiologica Sinica welcomes all the papers in the fields related to cardiovascular medicine including basic research, vascular biology, clinical pharmacology, clinical trial, critical care medicine, coronary artery disease, interventional cardiology, arrythmia and electrophysiology, atherosclerosis, hypertension, cardiomyopathy and heart failure, valvular and structure cardiac disease, pediatric cardiology, cardiovascular surgery, and so on. We received papers from more than 20 countries and areas of the world. Currently, 40% of the papers were submitted to Acta Cardiologica Sinica from Taiwan, 20% from China, and 20% from the other countries and areas in the world. The acceptance rate for publication was around 50% in general.